Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652270 | 0.83 | OPRD1 (0.37) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| SCHEMBL27387610 | 0.81 | OPRD1 (0.36) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| SCHEMBL27360345 | 0.81 | ALDH1A1 (0.38) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL27387046 | 0.81 | OPRD1 (0.36) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7953553 | 0.80 | ALDH1A1 (0.37) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| SCHEMBL13986461 | 0.71 | SMN1; SMN2 (0.40) | SIGMAR1OPRD1OPRM1CHRM5CHRM3 | |
| SCHEMBL16266998 | 0.70 | SLC6A2 (0.36) | OPRD1SMN1; SMN2SLC6A2SLC6A4CACNA1F | |
| SCHEMBL4754794 | 0.69 | SMN1; SMN2 (0.35) | SIGMAR1OPRD1OPRM1SMN1; SMN2SLC6A2 | |
| SCHEMBL7307461 | 0.69 | SMN1; SMN2 (0.37) | SIGMAR1OPRD1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL8039857 | 0.69 | SMN1; SMN2 (0.37) | SIGMAR1OPRD1CHRM5CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266787-A1 | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-12-30 | — | — | US | disclosed |
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | DR. REDDY'S LABORATORIES LIMITED DR. REDDY'S LABORATORIES, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2003104212-A1 | A NOVEL AMORPHOUS FORM OF [2-[4-[(4-CHLOROPHENYL)-PHENYL METHYL]-1- PIPERAZINYL] ETHOXY] ACETIC ACID DIHYDROCHLORIDE (CETIRIZINE DIHYDROCHLORIDE) | DR.REDDY'S LABORATORIES LTD. (IN) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104211-A2 | CRYSTALLINE [2-[4-[(4-CHLOROPHENYL)-PHENYL METHYL]-1-PIPERAZINYL] ETHOXY] ACETIC ACID DIHYDROCHLORIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132743-A1 | Amorphous form of (-)-[2-[4-[(4-Chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (levocetirizine dihydrochloride) | HRH4, HRH1, HRH2 | SIGMAR1 1262/4885OPRD1 1332/4885OPRM1 1517/4885 |
| US-20040266787-A1 | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof | CMA1, MAST1, ADRM1 | SIGMAR1 236/4885OPRD1 2527/4885OPRM1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.